Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Work In Process (2022 - 2025)

Arcutis Biotherapeutics has reported Work In Process over the past 4 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Work In Process at $5.0 million for Q4 2025, up 761.82% from a year ago — trailing twelve months through Dec 2025 was $5.0 million (up 761.82% YoY), and the annual figure for FY2025 was $5.0 million, up 761.82%.
  • Work In Process for Q4 2025 was $5.0 million at Arcutis Biotherapeutics, up from $4.7 million in the prior quarter.
  • Over the last five years, Work In Process for ARQT hit a ceiling of $5.0 million in Q4 2025 and a floor of $116000.0 in Q3 2022.
  • Median Work In Process over the past 4 years was $683500.0 (2024), compared with a mean of $1.5 million.
  • Biggest five-year swings in Work In Process: soared 1158.47% in 2024 and later tumbled 66.0% in 2025.
  • Arcutis Biotherapeutics' Work In Process stood at $395000.0 in 2022, then grew by 23.04% to $486000.0 in 2023, then rose by 20.16% to $584000.0 in 2024, then soared by 761.82% to $5.0 million in 2025.
  • The last three reported values for Work In Process were $5.0 million (Q4 2025), $4.7 million (Q3 2025), and $1.7 million (Q2 2025) per Business Quant data.